Amarin Corporation plc (NASDAQ: AMRN) Stock Competitors & Peer Comparison

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while LLY trades at $1,179.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas LLY's P/E ratio is 37.15. In terms of profitability, AMRN's ROE is -0.06%, compared to LLY's ROE of +0.93%. Regarding short-term risk, AMRN is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check LLY's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, JNJ has a market cap of 618B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while JNJ trades at $261.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas JNJ's P/E ratio is 23.90. In terms of profitability, AMRN's ROE is -0.06%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, AMRN is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check JNJ's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, ABBV has a market cap of 481.4B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while ABBV trades at $276.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas ABBV's P/E ratio is 26.74. In terms of profitability, AMRN's ROE is -0.06%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, AMRN is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check ABBV's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, MRK has a market cap of 351.7B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while MRK trades at $145.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas MRK's P/E ratio is 44.36. In terms of profitability, AMRN's ROE is -0.06%, compared to MRK's ROE of +0.07%. Regarding short-term risk, AMRN is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check MRK's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, NVS has a market cap of 272B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while NVS trades at $143.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas NVS's P/E ratio is 16.47. In terms of profitability, AMRN's ROE is -0.06%, compared to NVS's ROE of +0.30%. Regarding short-term risk, AMRN is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check NVS's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, AZN has a market cap of 246.2B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while AZN trades at $159.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas AZN's P/E ratio is 17.14. In terms of profitability, AMRN's ROE is -0.06%, compared to AZN's ROE of +0.22%. Regarding short-term risk, AMRN is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check AZN's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, AMGN has a market cap of 219.9B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while AMGN trades at $414.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas AMGN's P/E ratio is 18.21. In terms of profitability, AMRN's ROE is -0.06%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, AMRN is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check AMGN's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, GILD has a market cap of 182.4B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while GILD trades at $151.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas GILD's P/E ratio is -377.18. In terms of profitability, AMRN's ROE is -0.06%, compared to GILD's ROE of -0.16%. Regarding short-term risk, AMRN is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check GILD's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, NVO has a market cap of 169.4B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while NVO trades at $38.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas NVO's P/E ratio is 9.49. In terms of profitability, AMRN's ROE is -0.06%, compared to NVO's ROE of +0.59%. Regarding short-term risk, AMRN is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check NVO's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, PFE has a market cap of 158.7B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while PFE trades at $28.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas PFE's P/E ratio is 9.13. In terms of profitability, AMRN's ROE is -0.06%, compared to PFE's ROE of +0.05%. Regarding short-term risk, AMRN is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check PFE's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, BMY has a market cap of 121.7B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while BMY trades at $59.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas BMY's P/E ratio is 10.04. In terms of profitability, AMRN's ROE is -0.06%, compared to BMY's ROE of +0.47%. Regarding short-term risk, AMRN is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check BMY's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, SNY has a market cap of 96.6B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while SNY trades at $40.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas SNY's P/E ratio is 8.76. In terms of profitability, AMRN's ROE is -0.06%, compared to SNY's ROE of +0.06%. Regarding short-term risk, AMRN is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check SNY's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, GSK has a market cap of 93.2B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while GSK trades at $46.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas GSK's P/E ratio is 10.05. In terms of profitability, AMRN's ROE is -0.06%, compared to GSK's ROE of +0.24%. Regarding short-term risk, AMRN is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check GSK's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, BIIB has a market cap of 32.3B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while BIIB trades at $225.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas BIIB's P/E ratio is 13.79. In terms of profitability, AMRN's ROE is -0.06%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, AMRN is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check BIIB's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AMRN's ROE is -0.06%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AMRN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check HZNP's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, GRFS has a market cap of 6.3B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while GRFS trades at $7.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas GRFS's P/E ratio is 8.51. In terms of profitability, AMRN's ROE is -0.06%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, AMRN is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check GRFS's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while OGN trades at $13.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas OGN's P/E ratio is 4.11. In terms of profitability, AMRN's ROE is -0.06%, compared to OGN's ROE of +0.23%. Regarding short-term risk, AMRN is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check OGN's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, MIRA has a market cap of 29.5M. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while MIRA trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas MIRA's P/E ratio is -0.48. In terms of profitability, AMRN's ROE is -0.06%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, AMRN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check MIRA's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, SCLX has a market cap of 25.1M. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while SCLX trades at $2.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas SCLX's P/E ratio is -0.08. In terms of profitability, AMRN's ROE is -0.06%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, AMRN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check SCLX's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, SCLXW has a market cap of 21M. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while SCLXW trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AMRN's ROE is -0.06%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, AMRN is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check SCLXW's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, AMRN's ROE is -0.06%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, AMRN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check BDSIW's competition here

Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRN stands at 248M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AMRN is priced at $12.03 on the NASDAQ, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRN currently has a P/E ratio of -119.90, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AMRN's ROE is -0.06%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AMRN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check CRXT's competition here